In 2011, a study from UCLA suggested subjects given Byetta may have higher occurrences of pancreatic cancer and thyroid cancer.
(PRWEB) September 06, 2013
The diabetes drug resource center at DrugRisk.com is announcing updated information for patients taking the medication Byetta. A federal panel recently consolidated a growing number of lawsuits that allege the drug caused cancer*.
DrugRisk was created to increase patient safety by providing the latest recalls, safety alerts, research and litigation news to those taking popular prescription drugs. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Byetta is a popular injectable medication prescribed to those with type-II diabetes to lower blood sugar levels. However, the resource center has added information showing experts disagree about its safety.
In 2011, a study from UCLA suggested subjects given Byetta may have higher occurrences of pancreatic cancer and thyroid cancer**. This year, the Journal for the American Medical Association also advised that drugs like Byetta can double the risk of pancreatitis, a major risk factor for pancreatic cancer***.
The Institute for Safe Medication Practices has attributed a majority of serious diabetes drug side effect reports to the FDA to Byetta****. However, the FDA has not issued a recall or required new warning labels.
Now, DrugRisk has learned that, due to the growing number of patients who have filed a Byetta lawsuit alleging cancer, the Judicial Panel on Multidistrict Litigation has consolidated cases to a special multidistrict litigation federal court. (In Re: Incretin-Based Therapies Products Liability Litigation, MDL 2452, Southern District of California)*.
Anyone affected by cancer after taking Byetta is encouraged to visit the DrugRisk center or speak with a lawyer about their legal options. However, DrugRisk only recommends lawyers who have already handled these complex Byetta lawsuits.
For more information on the research, side effects and litigation news related to Byetta and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*JPML 8/26/13; jpml.uscourts.gov/sites/jpml/files/MDL-2452-Initial_Transfer-07-13.pdf
**Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
***JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
****ISMP QuarterWatch April, 2013.ismp.org/QuarterWatch/pdfs/2012Q3.pdf